CO6180446A2 - Compuestos de n-metilaminometil isoindol composiciones que los comprenden y metodos que utilizan los mismos - Google Patents
Compuestos de n-metilaminometil isoindol composiciones que los comprenden y metodos que utilizan los mismosInfo
- Publication number
- CO6180446A2 CO6180446A2 CO09034806A CO09034806A CO6180446A2 CO 6180446 A2 CO6180446 A2 CO 6180446A2 CO 09034806 A CO09034806 A CO 09034806A CO 09034806 A CO09034806 A CO 09034806A CO 6180446 A2 CO6180446 A2 CO 6180446A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- aryl
- benzyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
1.- Un compuesto de la fórmula (I):y sales, solvatos, estereoisómeros y profármacos farmacéuticamente aceptables del mismo, en donde: * denota centro quiral; X es CH2 o C=O; R1 es H, alquilo de (C1-C8), cicloalquilo de (C3-C7), alquenilo de (C2-C8), alquinilo de (C2-C8) bencilo, arilo, alquil de (C0-C4) -heterocicloalquilo de (C1-C6), alquilo de (C0-C4) -heteroarilo de (C2-C9), C(O)R3, C(S)R3, C(O)OR4, (alquilo de C1-C8) -N (R6)2, alquilo de (C1-C8) -OR5, alquilo de (C1-C8)-C(O)OR5, C(O)NHR3, C(S)NHR3, C(O)NR3R3´, C(S)NR3R3 o alquilo de (C1-C8)-O(CO)R5 ;R2 es H, CH3, o alquilo de(C2-C8) ;R3 y R3' son independientemente alquilo de (C1-C8); cicloalquilo de (C3-C7); alquenilo de (C2-C8); alquinilo de (C2-C8); bencilo; alquilo de (C0-C4) - arilo de (C5-C10), opcionalmente sustituido con uno o más de: alquilo de (C1-C6), dicho alquilo opcionalmente sustituido con uno o más de halógeno, alcoxi de (C1-C6), dicho alquilo opcionalmente sustituido con uno o más de halógeno, SCY3, en donde Y es hidrógeno o halógeno, NZ2, en donde Z es hidrógeno o alquilo de (C1-C6) alquilenodioxi de (C1-C6), o halógeno; alquilo de (C0-C4) -heterocicloalquilo de (C1-C6) alquilo de (C0-C4) -heteroarilo de (C2-C9); alquilo de (C0-C8)-N(R6)2;alquilo de (C1-C8) -OR5; alquilo de (C1-C8)-C(O)OR5; alquilo de (C1-C8)-O(CO)R5; o C(O)OR5; R4 es alquilo de (C1-C8), alquenilo de (C2-C8) alquinilo de (C2-C8), alquilo de (C1-C4)-OR5, bencilo, arilo, alquilo de (C0-C4) -heterocicloalquilo de (C1-C6), o alquilo de (C0-C4) -heteroarilo de (C2-C9); R5 es alquilo de (C1-C8) , alquenilo de (C2-C8), alquinilo de (C2-C8), bencilo, arilo de (C5-C10), o heteroarilo de (C2-C9); cada vez que R6 es independientemente H, alquilo de (C1-C8), alquenilo de (C2-C8) , alquinilo de (C2-C8), bencilo, arilo de (C5-C10), heteroarilo de (C2-C9), o alquilo de (C0-C8) -C(O)O-R5, o dos grupos R6 pueden unirse para formar un grupo heterocicloalquilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84522706P | 2006-09-15 | 2006-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6180446A2 true CO6180446A2 (es) | 2010-07-19 |
Family
ID=38983295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09034806A CO6180446A2 (es) | 2006-09-15 | 2009-04-03 | Compuestos de n-metilaminometil isoindol composiciones que los comprenden y metodos que utilizan los mismos |
Country Status (30)
Country | Link |
---|---|
US (2) | US8648096B2 (es) |
EP (1) | EP2076260B1 (es) |
JP (1) | JP5567339B2 (es) |
KR (1) | KR20090050107A (es) |
CN (2) | CN103382197A (es) |
AR (1) | AR062875A1 (es) |
AT (1) | ATE502634T1 (es) |
CA (1) | CA2663376C (es) |
CL (1) | CL2007002670A1 (es) |
CO (1) | CO6180446A2 (es) |
CR (1) | CR10696A (es) |
CY (1) | CY1112558T1 (es) |
DE (1) | DE602007013436D1 (es) |
DK (1) | DK2076260T3 (es) |
ES (1) | ES2361584T3 (es) |
HR (1) | HRP20110261T1 (es) |
IL (1) | IL197566A0 (es) |
MX (1) | MX2009002666A (es) |
NI (1) | NI200900031A (es) |
NZ (1) | NZ575689A (es) |
PE (1) | PE20080832A1 (es) |
PL (1) | PL2076260T3 (es) |
PT (1) | PT2076260E (es) |
RS (1) | RS51725B (es) |
RU (1) | RU2009114159A (es) |
SI (1) | SI2076260T1 (es) |
TW (1) | TW200819435A (es) |
UA (1) | UA95975C2 (es) |
WO (1) | WO2008033567A1 (es) |
ZA (1) | ZA200901852B (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006028964A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
PT2380887E (pt) * | 2005-06-30 | 2013-09-18 | Celgene Corp | Processos para a preparação de compostos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona |
JP5567339B2 (ja) * | 2006-09-15 | 2014-08-06 | セルジーン コーポレイション | N−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法 |
US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
PE20140963A1 (es) | 2008-10-29 | 2014-08-06 | Celgene Corp | Compuestos de isoindolina para el tratamiento de cancer |
MX2011001555A (es) | 2008-12-19 | 2011-04-14 | Graceway Pharmaceuticals Llc | Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica. |
EP2453747B1 (en) * | 2009-07-13 | 2017-08-30 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
RS58523B1 (sr) | 2010-02-11 | 2019-04-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe |
EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
EP2968334A4 (en) | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970134B1 (en) | 2013-03-14 | 2018-02-28 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
CA2903264A1 (en) | 2013-03-14 | 2014-11-06 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
EP2970132B1 (en) | 2013-03-14 | 2020-09-23 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9765035B2 (en) | 2013-03-14 | 2017-09-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US20140314752A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
AU2015300825B2 (en) | 2014-08-07 | 2019-10-10 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
PT3643709T (pt) * | 2014-10-30 | 2021-12-20 | Kangpu Biopharmaceuticals Ltd | Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
WO2017040376A1 (en) * | 2015-08-31 | 2017-03-09 | The University Of Toledo | Potent phthalate inhibitors of aspartate n-acetyltransferase and selective aspartate pathway inhibitors |
EP3390396B1 (en) | 2015-12-15 | 2022-07-06 | Astrazeneca AB | Isoindole compounds |
CA3020281A1 (en) * | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
US20190255041A1 (en) | 2016-10-28 | 2019-08-22 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
WO2018229155A1 (en) | 2017-06-14 | 2018-12-20 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
CN111278815B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 戊二酰亚胺 |
WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
CA3092677A1 (en) * | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
LT3784663T (lt) * | 2018-04-23 | 2023-10-25 | Celgene Corporation | Pakeistieji 4-aminoizoindolin-1,3-diono junginiai ir jų naudojimas limfomos gydymui |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
SG11202109024YA (en) | 2019-04-12 | 2021-09-29 | C4 Therapeutics Inc | Tricyclic degraders of ikaros and aiolos |
BR112022007386A2 (pt) * | 2019-10-21 | 2022-07-05 | Celgene Corp | Métodos para tratar um câncer hematológico e o uso de biomarcadores companheiros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona |
EP4048279A1 (en) | 2019-10-21 | 2022-08-31 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
CN110746400B (zh) * | 2019-11-07 | 2021-12-17 | 郑州大学 | 一种靶向雄激素受体的荧光探针及其制备方法 |
CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
TR200101503T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
CA2508171C (en) * | 2002-12-13 | 2012-08-28 | Cytopia Pty Ltd | Nicotinamide-based kinase inhibitors |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
PT2380887E (pt) * | 2005-06-30 | 2013-09-18 | Celgene Corp | Processos para a preparação de compostos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona |
JP5567339B2 (ja) * | 2006-09-15 | 2014-08-06 | セルジーン コーポレイション | N−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法 |
-
2007
- 2007-09-14 JP JP2009528337A patent/JP5567339B2/ja active Active
- 2007-09-14 ZA ZA200901852A patent/ZA200901852B/xx unknown
- 2007-09-14 DK DK07838415.3T patent/DK2076260T3/da active
- 2007-09-14 ES ES07838415T patent/ES2361584T3/es active Active
- 2007-09-14 SI SI200730569T patent/SI2076260T1/sl unknown
- 2007-09-14 CA CA2663376A patent/CA2663376C/en active Active
- 2007-09-14 UA UAA200903664A patent/UA95975C2/ru unknown
- 2007-09-14 CL CL200702670A patent/CL2007002670A1/es unknown
- 2007-09-14 RU RU2009114159/15A patent/RU2009114159A/ru not_active Application Discontinuation
- 2007-09-14 TW TW096134612A patent/TW200819435A/zh unknown
- 2007-09-14 PT PT07838415T patent/PT2076260E/pt unknown
- 2007-09-14 CN CN2013102182141A patent/CN103382197A/zh active Pending
- 2007-09-14 CN CNA2007800424312A patent/CN101534820A/zh active Pending
- 2007-09-14 EP EP07838415A patent/EP2076260B1/en active Active
- 2007-09-14 US US11/901,291 patent/US8648096B2/en active Active
- 2007-09-14 DE DE602007013436T patent/DE602007013436D1/de active Active
- 2007-09-14 KR KR1020097006986A patent/KR20090050107A/ko not_active Application Discontinuation
- 2007-09-14 AT AT07838415T patent/ATE502634T1/de active
- 2007-09-14 PL PL07838415T patent/PL2076260T3/pl unknown
- 2007-09-14 RS RS20110258A patent/RS51725B/en unknown
- 2007-09-14 MX MX2009002666A patent/MX2009002666A/es active IP Right Grant
- 2007-09-14 NZ NZ575689A patent/NZ575689A/en not_active IP Right Cessation
- 2007-09-14 WO PCT/US2007/020201 patent/WO2008033567A1/en active Application Filing
- 2007-09-17 PE PE2007001253A patent/PE20080832A1/es not_active Application Discontinuation
- 2007-09-17 AR ARP070104112A patent/AR062875A1/es unknown
-
2009
- 2009-03-12 IL IL197566A patent/IL197566A0/en unknown
- 2009-03-13 NI NI200900031A patent/NI200900031A/es unknown
- 2009-03-30 CR CR10696A patent/CR10696A/es not_active Application Discontinuation
- 2009-04-03 CO CO09034806A patent/CO6180446A2/es not_active Application Discontinuation
-
2011
- 2011-04-12 HR HR20110261T patent/HRP20110261T1/hr unknown
- 2011-05-20 CY CY20111100500T patent/CY1112558T1/el unknown
-
2013
- 2013-12-30 US US14/144,292 patent/US20140113935A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6180446A2 (es) | Compuestos de n-metilaminometil isoindol composiciones que los comprenden y metodos que utilizan los mismos | |
AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
NO20084983L (no) | Aminderivat med NPY Y5 reseptorantagonistaktivitet | |
AR083798A1 (es) | Inhibidores selectivos de glucosidasas y sus usos | |
AR068055A1 (es) | Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met | |
AR092073A1 (es) | Inhibidores de neprilisina | |
RU2013146550A (ru) | Ингибиторы глюкозилцерамид-синтазы | |
PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
PE20170024A1 (es) | Compuestos de 6,8-dioxabiciclo [3.2.1] octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr | |
AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
CO6430424A2 (es) | Compuestos sustituidos de espiro-amida | |
AR068912A1 (es) | Derivados de 6- aril/ heteroarilquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y utilizacion como inhibidores de cmet | |
AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
AR082985A1 (es) | INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION | |
ECSP088858A (es) | Uso de bifenilamidas de ácido arilcarboxílico para el tratamiento de semillas | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
CO5630005A2 (es) | Triazolopirimidinas sustituidas, procedimientos para su obtencion y el uso de las mismas para combatir hongos, asi como productos que las contienen | |
ECSP11010912A (es) | Compuestos de pirrol | |
PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
AR083694A1 (es) | USO DE COMPUESTOS FARMACEUTICOS ACTIVOS PARA EL TRATAMIENTO DE ESTADOS PATOLOGICOS DEL SISTEMA NERVIOSO CENTRAL, COMPOSICION FARMACEUTICA, MODULADOR ALOSTERICO NEGATIVO DEL GABA A a5, METODO | |
AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
AR061106A1 (es) | Pteridinas sustituidas y composiciones farmaceuticas que las contienen. | |
EA201600241A1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |